¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"SAR : structure activity relationship"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • electrical activity
    Àü±âȰ¼º
  • enzyme activity
    È¿¼ÒȰ¼º, È¿¼ÒȰ¼ºµµ
  • fibrinolytic activity
    ¼¶À¯¼Ò¿ëÇØ´É, ÇǺ기¿ëÇØ´É
  • helper cell activity
    µµ¿ò¼¼Æ÷Ȱ¼º
  • hemolytic activity
    ¿ëÇ÷´É
  • homosexual activity
    µ¿¼º¾ÖÇàÀ§
  • involuntary activity
    ºÒ¼öÀÇȰµ¿
  • insertion activity
    »ðÀÔȰµ¿ÀüÀ§
  • insulin-like activity
    Àν¶¸°À¯»çȰ¼ºµµ
  • integrated neural activity
    ÅëÇսŰæÈ°¼º
  • molar activity
    ¸ôȰ¼º
  • mental activity
    Á¤½ÅȰµ¿
  • psychomotor activity
    Á¤½Å¿îµ¿È°µ¿
  • partial agonistic activity
    ºÎºÐÀÛ¿ëÁ¦È°¼º
  • specific activity
    1. ºñ¹æ»ç´É 2. ºñ(Ýï)Ȱ¼ºµµ, °íÀ¯È°¼ºµµ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • core structure
    Á߽ɱ¸Á¶¹°
  • decidual structure
    Å»¶ô¸·±¸Á¶
  • discoid structure
    ¿ø¹Ý±¸Á¶
  • electron structure
    ÀüÀÚ±¸Á¶
  • immunoglobulin structure
    ¸é¿ª±Û·ÎºÒ¸°±¸Á¶
  • structure
    ±¸Á¶
  • activity
    Ȱ¼ºµµ, Ȱµ¿
  • activity therapist
    Ȱµ¿¿ä¹ý»ç, Ȱµ¿Ä¡·á»ç
  • activity therapy
    Ȱµ¿¿ä¹ý
  • antibacterial activity
    Ç×±ÕÀÛ¿ë
  • caries activity
    ¿ì½ÄȰµ¿¼º
  • electrical activity
    Àü±âȰµ¿
  • enzyme activity
    È¿¼ÒȰ¼º, È¿¼ÒȰ¼ºµµ
  • fibrinolytic activity
    ¼¶À¯¼Ò¿ëÇØ´É
  • helper cell activity
    µµ¿ò¼¼Æ÷´É, Á¶·Â¼¼Æ÷´É
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • activity
    Ȱ¼ºµµ(üÀàõöô), Ȱµ¿µµ(üÀÔÑöô), Ȱ¼º(üÀàõ).
  • activity
    ¹æ»ç´É, Ȱ¼ºµµ
  • activity therapist
    Ȱµ¿ ¿ä¹ý»ç
  • activity therapy
    Ȱµ¿¿ä¹ý(¡­èþÛö).
  • activity therapy
    Ȱµ¿ ¿ä¹ý
  • activity, antibacterial
    Ç×±ÕÀÛ¿ë
  • amylase activity
    ¾Æ¹Ð¶óÁ¦-Ȱ¼ºµµ
  • antibacterial activity
    Ç×±ÕÀÛ¿ë(ù÷жíÂéÄ), Ç×±ÕȰ¼º(ù÷жüÀàõ).
  • functional activity
    ±â´É¼º Ȱ¼ºµµ<Ȱµ¿µµ>
  • fusion activity
    À¶ÇÕ´É
  • glucagon activity
    ±Û·çÄ«°ïȰ¼ºµµ.
  • helper cell activity
    Á¶·Â¼¼Æ÷´É, º¸Á¶¼¼Æ÷´É
  • hemolytic activity
    ¿ëÇ÷´É
  • homosexual activity
    µ¿¼º¾ÖÀû ÇàÀ§
  • plasma histaminase activity
    Ç÷ÀåÈ÷½ºÅ¸¹Ì³ª¾ÆÁ¦È°¼ºµµ.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • host-parasite relationship
    ¼÷ÁÖ±â»ýü°ü°è
  • peer relationship
    µ¿·á°ü°è, ¶Ç·¡°ü°è
  • therapeutic relationship
    Ä¡·áÀû °ü°è(~μÌõ).
  • time dose relationship
    ½Ã°£¿ë·®°ü°è.
  • working relationship
    ±Ù¹«°ü°è(Ë»ËÎË´Ë­).
  • alveolar structure
    Æ÷»ó±¸Á¶(¡­Ï°ðã).
  • alveolar structure
    ÆóÆ÷±¸Á¶(¡­Ï°ðã)
  • antibody structure
    Ç×ü±¸Á¶(¡­Ï°ðã).
  • antigenic structure
    Ç׿ø±¸Á¶(¡­Ï°ðã).
  • atomic structure
    ¿øÀÚ±¸Á¶(¡­Ï°ðã).
  • atomic structure
    ¿øÀÚ±¸Á¶
  • bone structure
    »À±¸Á¶, °ñ±¸Á¶(Íéϰðã).
  • chain structure
    ¿¬¼â±¸Á¶(ææáðϰðã).
  • chemical structure
    È­ÇÐÀû ±¸Á¶
  • chemical structure
    È­Çб¸Á¶(¡­Ï°ðã).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • specific activity
    ºñȰ¼º(ÝïüÀàõ)
  • suppressible insulin-like activity
    ¾ï¾Ð °¡´É(åääâʦÒö) Àν¶¸°À¯»çȰ¼º(×¾ÞÄüÀàõ)
  • surface activity
    Ç¥¸éȰ¼º (øúØüüÀàõ)
  • vibrational optical activity
    Áøµ¿ ±¤ÇРȰ¼º(òÉÔÑÎÃùÊ üÀàõ)
  • beta structure
    º£Å¸ ±¸Á¶(ϰðã)
  • bubble structure
    °Åǰ±¸Á¶(ϰðã)
  • chi structure
    Ä«ÀÌ ±¸Á¶(ϰðã)
  • cholesteric structure
    ÄÝ·¹½ºÅ׸¯ ±¸Á¶(ϰðã)
  • cointegrate structure
    °øÅëÇÕ±¸Á¶(Íì÷×ùêϰðã)
  • contributing structure
    "Âü¿©±¸Á¶(óÑæ¨Ï°ðã), (ÔÒ) canonical structure"
  • covalent structure analysis
    °øÀ¯°áÇÕ ±¸Á¶ºÐ¼®(ÍìêóÌ¿ùêϰðãÝÂà°)
  • eye structure
    ´« ±¸Á¶ (ϰðã)
  • fine-structure genetic mapping
    ¹Ì¼¼ ±¸Á¶(Ú°á¬Ï°ðã) À¯ÀüÀÚ ÀÛµµ(ë¶îîí­íÂÓñ)
  • genetic fine structure
    À¯Àü ¹Ì¼¼±¸Á¶(ë¶îîÚ°á¬Ï°ðã)
  • Greek-key structure
    ±×¸®½º¿­¼è ±¸Á¶(ϰðã)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
SA salicylic acid; saline [solution]; salt added; sarcoidosis; sarcoma; scalenus anticus; secondary ame...
ECG Electro-Cardio-Graphy(-Gram); ½ÉÀüµµ
   = EKG
  1. Conducting System Structu...
DPFR diastolic pressure-flow relationship
ESFL end-systolic force-length relationship
ESPVR end-systolic pressure-volume relationship
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
ESPVR End-systolic pressure-volume relationship
LSER Linear Solvation Energy Relationship
LFER linear free energy relationship
Gly-Sar Glycylsarcosine
SAR Saralasin
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • sibling relationship
    ÇüÁ¦ Àڸаü°è
  • specific dentist-patient relationship
    µ¶Æ¯ÇÑ Ä¡°ú ÀÇ»ç-ȯÀÚ °ü°è
  • symbiotic relationship
    °ø»ý °ü°è
  • temporal relationship
    ½Ã°£Àû °ü·Ã¼º
  • working relationship
    ±Ù¹«°ü°è
  • ancillary structure
    º¸Á¶ Á¶Á÷
  • atomic structure
    ¿øÀÚ ±¸Á¶
  • bone structure
    °ñ°Ý, »À ±¸Á¶, °ñ ±¸Á¶
    µ¿¹°ÀÇ ¸öÀ» ÁöÅÊÇϰí üÇüÀ» Çü¼ºÇÏ´Â ±â°ü. ü°Ý ¶Ç´Â ÀÚ¼¼¸¦ ÁöÅÊÇϸç, ¿îµ¿ÀÇ Åä´ë°¡ µÇ°í, ³»ÀåÀÇ ¸ðµç ±â°üÀ» º¸È£ÇÏ´Â ¿ªÇÒÀ» ÇÑ´Ù. ôÃßµ¿¹°¿¡¼­´Â ±âº»ÀûÀ¸·Î °ñ°Ý¿¡ °øÅëÁ¡ÀÌ Àִµ¥, µÎ°ñ°ú ôÃß°¡ Áß½ÉÀ» ÀÌ·ç¸ç, °Å±â¿¡ »çÁö°ñÀÌ À̾îÁø´Ù. µ¿¹°ÀÇ Á¾·ù¿¡ µû¶ó¼­ °ñ°ÝÀÇ Çü»óÀ̳ª ¼ö·® µî¿¡´Â Â÷À̰¡ ÀÖ´Ù. °ñ°ÝÀÇ °áÇÕ ¹æ¹ý¿¡´Â ´ÙÀ½ÀÇ 3Á¾·ù°¡ ÀÖ´Ù. ¨ç °üÀý °áÇÕ : °ñ°ÝÀÇ ´ëºÎºÐÀº °üÀý·Î¼­ ¿òÁ÷À̵µ·Ï µÇ¾î ÀÖ´Ù. ¨è ºÀÇÕ : µÎ°³°ñÀº °ñ°ÝÀÇ °áÇպκÐÀÌ Åé´Ïó·³ µÇ¾î ÀÖ¾î Åé´Ï¹ÙÄû¸¦ ¸ÂÃá µíÀÌ °áÇյǾî ÀÖ´Ù. ¨é ¿¬°ñ °áÇÕ : Á¿ìÀÇ Ä¡°ñÀ̳ª ôÃß°ñ »çÀÌ¿¡´Â ¿¬°ñ Á¶Á÷ÀÌ ÀÖ¾î ±×°ÍÀÌ °ñ°Ý°ú °ñ°ÝÀ» °áÇÕ½ÃŲ´Ù.
  • capsule structure
    ³¶ ±¸Á¶, °üÀý³¶ ±¸Á¶
  • chain structure
    ¿¬¼â ±¸Á¶
  • chemical structure
    È­ÇÐ ±¸Á¶
  • cubic structure
    µî¹æ ±¸Á¶, ÀÔ¹æ ±¸Á¶
  • decidua structure
    Å»¶ô¸· ±¸Á¶
  • diencephalic structure
    °£³ú ±¸Á¶
  • domain structure
    ¿µ¿ª ±¸Á¶
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
activity coefficient <chemistry> The factor by which the value of a concentration of a solute must be multiplied to determine its true thermodynamic activity.
(06 May 1997)
activity cycles Bouts of physical irritability or movement alternating with periods of quiescence. It includes biochemical activity and hormonal activity which may be cellular. These cycles are shorter than 24 hours and include sleep-wakefulness cycles and the periodic activation of the digestive system.
(12 Dec 1998)
activity, drug A measure of the physiological response a drug produces in the body. A less active drug produces less response (and visa versa).
(12 Dec 1998)
blocking activity The repression or elimination of electrical activity in the brain by the arrival of a sensory stimulus.
(05 Mar 2000)
blood bactericidal activity Native bactericidal property of blood due to normally occurring antibacterial substances such as beta lysin, leukin, etc.
(12 Dec 1998)
melanoma growth stimulatory activity Cytokine of the C X C subfamily. Potent mitogen. Activates and is chemotactic for, neutrophils.
(18 Nov 1997)
water activity <chemistry> An expression of the relative availability of water in a substance. Pure water has an water activity of 1.000. The water activity of a solution is one-hundredth its relative humidity.
(09 Oct 1997)
motor activity The physical activity of an organism as a behavioural phenomenon.
(12 Dec 1998)
complement haemolytic activity assay Usual screening assay for complement. Dilutions of the serum to be tested are added to antibody-coated erythrocytes and the percentage of lysis is measured. The values are expressed by ch50, haemolytic complement units per milliliter, which is the dilution of serum required to lyse 50 percent of the erythrocytes in the assay.
(12 Dec 1998)
plasma renin activity The estimation of renin in plasma by measuring the rate of formation of angiotensin I or II.
(05 Mar 2000)
solar activity Any type of variation in the appearance of energy output of the sun.
(12 Dec 1998)
specific activity 1. <chemistry> The number of activity units (whatever is appropriate) per unit of mass, volume or molarity.
2. <radiobiology> Total activity of a given nuclide per gram of a compound, element or radioactive nuclide. Perhaps most often usage, in the context of radiochemicals, the number of microcuries per micromole.
(16 Dec 1997)
nonsuppressible insulin-like activity A blood protein (nsila) which mimics the biological activity of insulin in serum, but is not suppressed by insulin antibodies. During acid-ethanol extraction of cohn fraction III, 10% of the activity is found in the supernatant (nsila-s) and the remaining activity in the precipitate (nsila-p). The latter is a large molecular compound, much less stable than the soluble fraction. Nsila-s is a more potent growth factor than insulin and exhibits sulfation activity.
(12 Dec 1998)
drug activity A measure of the physiological response a drug produces. A less active drug produces less response (and visa versa).
(12 Dec 1998)
insulin-like activity A measure of substances, usually in plasma, that exert biologic effects similar to those of insulin in various bioassays; sometimes used as a measure of plasma insulin concentrations; always gives higher values than immunochemical techniques for the measurement of insulin.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • primary structure
    ÃÊ¿øÀû ±¸Á¶¹°(ÃÖ¼ÒÇÑÀÇ Á¶Çü ¼ö´ÜÀ¸·Î Á¦À۵Ǵ ÀüÀ§ Á¶°¢)
  • structure
    ¹°
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á